GH-RH Peptide Analogs for Potent Antitumor Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GH-RH antagonists have limited potency and specificity in inhibiting growth hormone release and cancer cell proliferation, particularly in tumors with unique GH-RH receptors different from those in the pituitary, and lack direct antitumor effects.
Innovation Solution
Development of novel synthetic analogs of hGH-RH(1-29)NH2 and hGH-RH(1-30)NH2 peptides with specific amino acid replacements, such as [A0-Tyr1-D-Arg2, A4, A6, A8, Har9, Tyr(Me)10, A11, A12, Abu15, A17, A20, A21, Nle27, D-Arg28, A29-A30-A31]hGH-RH(1-29)NH2, which exhibit enhanced inhibitory potencies on both pituitary and cancer cells through direct action on GH-RH receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional GH-RH antagonists are used, then growth hormone release is inhibited, but the inhibitory potency is limited and direct antitumor effects are absent
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at specific positions (N-terminal positions 0-3 and C-terminal positions 26-31) of the GH-RH peptide structure. These chemical parameter changes in the peptide sequence enhance both the inhibitory potency against growth hormone release and the direct antitumor effects, transforming the molecular properties to achieve dual therapeutic benefits.
Solution Approach 2:
The invention applies local quality by making specific localized modifications at the N-terminal and C-terminal regions of the GH-RH peptide while maintaining the integrity of the central core structure. These localized amino acid replacements at specific positions create regions of enhanced biological activity without disrupting the overall peptide framework, achieving improved potency and direct antitumor effects.
2Reliability
If conventional GH-RH antagonists are used, then pituitary GH release is inhibited, but specificity against tumors with unique GH-RH receptors is limited
Solution Approach 1:
The patent applies universality by designing analogs that simultaneously target multiple receptor types - both pituitary GH-RH receptors and tumor-specific GH-RH receptors. The modified peptide structure achieves multi-functionality by maintaining affinity for conventional pituitary receptors while gaining enhanced binding capability to unique tumor receptors, allowing a single agent to address both endocrine and neoplastic pathways.
Solution Approach 2:
The invention uses parameter changes in the amino acid sequence to enhance receptor specificity. By modifying residues at positions 0-3 and 26-31, the peptide's binding parameters are optimized to distinguish between and effectively target different receptor subtypes expressed in pituitary versus tumor tissues, achieving improved specificity and adaptability.
3Reliability
If GH-RH analogs with enhanced potency are developed, then direct antitumor effects are achieved, but the complexity of peptide synthesis increases
Solution Approach 1:
The patent applies segmentation by dividing the peptide modification strategy into distinct modular sections - N-terminal modifications (positions 0-3) and C-terminal modifications (positions 26-31). This segmented approach allows for systematic optimization of each region's contribution to antitumor activity while facilitating modular synthesis and characterization, thereby managing the complexity of manufacturing through structured design.
Data Source
AI summary
There is provided a novel series of synthetic analogs of hGH-RH(1-29)NH2 (SEQ ID NO: 1) and hGH-RH(1-30)NH2. Of particular interest are those carrying PhAc, N-Me-Aib, Dca, Ac-Ada, Fer, Ac-Amc, Me-NH-Sub, PhAc-Ada, Ac-Ada-D-Phe, Ac-Ada-Phe, Dca-Ada, Dca-Amc, Nac-Ada, Ada-Ada, or CH3—(CH2)10—CO-Ada, at the N-Terminus and β-Ala, Amc, Apa, Ada, AE2A, AE4P, ε-Lys(α-NH2), Agm, Lys(Oct) or Ahx, at the C-terminus. These analogs inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers, and inhibit the hyperplastic and benign proliferative disorders of various organs, through a direct effect on the cancerous and non-malignant cells. The stronger inhibitory potencies of the new analogs, as compared to previously described ones, result from replacement of various amino acids.